Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry
Uro-Oncology
Related content
Uro-Oncology
Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer
Prostate Cancer Prostatic Dis.
Nair SM, Peters M, Kurver P, Lavi A, Verhoeff JJC, van der Voort van Zyp JRN, van Son MJ, Chin JL
doi: 10.1038/s41391-020-00265-5.
Erectile and Sexual Functions and DysfunctionsUrinary IncontinenceUro-Oncology
Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade
Cancer Med.
Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL
doi: 10.1002/cam4.1103.
Erectile and Sexual Functions and DysfunctionsHPV and Gynecologic Cancer
Sexual Inactivity During the Last 4 Weeks in Long-Term Cervical Cancer Survivors: Prevalence and Associated Factors
J Sex Med.
Dahl AA, Bentzen AG, Fosså SD, Hess SL, Steen R, Vistad I, Kiserud CE
doi: 10.1016/j.jsxm.2020.03.010.
Uro-Oncology
Early-Life Cardiorespiratory Fitness and Long-Term Risk of Prostate Cancer
Cancer Epidemiol Biomarkers Prev.
Crump C, Stattin P, Brooks JD, Stocks T, Sundquist J, Sieh W, Sundquist K
doi: 10.1158/1055-9965.EPI-20-0535.
COMMENTED
Uro-Oncology
Long-term oncological and functional follow-up in low dose rate brachytherapy (LDR-BT) for prostate cancer: results from the prospective nation-wide Swiss Registry
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
BJU Int.
Viktorin P, Putora PM, Schmid HP, Plasswilm L, Schwab C, Thoeni A, Hochreiter W, Prikler L, Suter S, Stucki P, Müntener M, Blick N, Schiefer H, Güsewell S, Zürn K, Engeler D
doi: 10.1111/bju.15003.
Further Publications Gynecology
Fertility status among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: results of the 58 Late Adverse Effects study
Hum Reprod
Rossi G, Kicinski M, Suciu S, Vandecruys E, Plat G, Uyttebroeck A, Paillard C, Barbati M, Dresse MF, Simon P, Minckes O, Pluchart C, Ferster A, Freycon C, Millot F, van der Werff Ten Bosch J, Chantrain C, Paulus R, de Rojas T, de Schaetzen G, Rohrlich P, Benoit Y, Piette C
doi: 10.1093/humrep/deab236
Benign Prostatic Hyperplasia (BPH)HypogonadismLower Urinary Tract SymptomsUro-Oncology
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men
BJU Int.
Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schröder FH, Jones TH, Porst H, Hackett G, Wheaton OA, Martin-Morales A, Meuleman E, Cunningham GR, Divan HA, Rosen RC; RHYME Investigators
doi: 10.1111/bju.13578.
Uro-Oncology
Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study
Prostate.
Lundgren PO, Kjellman A, Norming U, Gustafsson O
doi: 10.1002/pros.23991.
Uro-Oncology
Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities
Prostate.
Dee EC, Nezolosky MD, Chipidza FE, Arega MA, Butler SS, Sha ST, Mahal BA, Nguyen PL, Yang DD, Muralidhar V
doi: 10.1002/pros.24041.